AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25849627 — intervention group
Group type: EXPERIMENTAL
Intervention: VILI among women with CD4+ count ≥ 350
Number of subjects: 654
Study 23279405 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced assessors
Number of subjects: 78
Study 23279405 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer assessment
Number of subjects: 78
Study 23279405 — intervention group
Group type: COMPARATOR
Intervention: Digital scanning device (Prepassistant)
Number of subjects: 78
Study 21562066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose before PCI
Number of subjects: 82
Study 21562066 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous myocardial infarction
Number of subjects: 82
Study 21562066 — intervention group
Group type: COMPARATOR
Intervention: Traditional and non-traditional risk markers (IL‐1β, IL‐6, TNF‐α, hsCRP, interferon gamma, leptin, IGF‐I, insulin, proinsulin, NT‐proBNP)
Number of subjects: 82
Study 18253024 — intervention group
Group type: EXPERIMENTAL
Intervention: Information leaflet sent by postal mail
Number of subjects: 860
Study 18253024 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leaflet sent)
Number of subjects: 860
Study 17236635 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane/N2O/fentanyl anesthesia with rocuronium 0.6 mg/kg
Number of subjects: 40
Study 17236635 — intervention group
Group type: COMPARATOR
Intervention: Propofol/N2O/fentanyl anesthesia with rocuronium 0.6 mg/kg
Number of subjects: 40
Study 12851747 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg 17beta‐estradiol implant
Number of subjects: 40
Study 12851747 — intervention group
Group type: COMPARATOR
Intervention: Placebo implant
Number of subjects: 40
Study 10866913 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 4%
Number of subjects: 63
Study 10866913 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 63
Study 10866913 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 63
Study 9175118 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary reward
Number of subjects: 10
Study 9175118 — intervention group
Group type: COMPARATOR
Intervention: 'Ok' reinforcer
Number of subjects: 10
Study 8400558 — intervention group
Group type: COMPARATOR
Intervention: Mn-DPDP at a concentration of 50 mumol/mL
Number of subjects: 20
Study 8400558 — intervention group
Group type: COMPARATOR
Intervention: Mn-DPDP at a concentration of 10 mumol/mL
Number of subjects: 20
Study 8400558 — intervention group
Group type: EXPERIMENTAL
Intervention: Mn-DPDP
Number of subjects: 20
Study 3511308 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of metoprolol once daily
Number of subjects: 562
Study 3511308 — intervention group
Group type: COMPARATOR
Intervention: 25 mg of hydrochlorothiazide once daily
Number of subjects: 562
Study 29625120 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left primary somatosensory cortex (S1) applied repeatedly over five days.
Number of subjects: 0
Study 29625120 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left primary somatosensory cortex (S1).
Number of subjects: 0
Study 27255167 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved housing and LLINs
Number of subjects: 800
Study 27255167 — intervention group
Group type: COMPARATOR
Intervention: LLINs alone
Number of subjects: 800
Study 24327175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 2 × 2 mg for five consecutive days
Number of subjects: 0
Study 24327175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22398360 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical pump (Group M)
Number of subjects: 100
Study 22398360 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 100
Study 20123322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory threshold (VT) determination using the V-Slope method
Number of subjects: 428
Study 20123322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer variability assessment
Number of subjects: 428
Study 20123322 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer variability in a second core lab
Number of subjects: 428
Study 20123322 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-laboratory variability
Number of subjects: 428
Study 15591079 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU of rFSH (group I, n = 26)
Number of subjects: 52
Study 15591079 — intervention group
Group type: COMPARATOR
Intervention: 300 IU of rFSH (group II, n = 26)
Number of subjects: 52
Study 12186198 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly doses of 2 x 60 mg iron (one tablet each Friday morning and evening)
Number of subjects: 172
Study 12186198 — intervention group
Group type: COMPARATOR
Intervention: Daily dose of 1 x 60 mg iron
Number of subjects: 172
Study 10483942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (2.5 microg/min)
Number of subjects: 30
Study 10483942 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study 8700433 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer conferencing for receiving course assignments and interaction with faculty
Number of subjects: 0
Study 1927616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine IV, 2 mg per hour for up to 7 days
Number of subjects: 351
Study 1927616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 7011688 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 g aspirin
Number of subjects: 24
Study 7011688 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg azapropazone
Number of subjects: 24
Study 7011688 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and azapropazone together
Number of subjects: 24
Study 7011688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7011688 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone
Number of subjects: 24
Study 30930429 — intervention group
Group type: EXPERIMENTAL
Intervention: evolocumab plus standard of care (SOC)
Number of subjects: 556
Study 30031874 — intervention group
Group type: EXPERIMENTAL
Intervention: Grating acuity at 12 months of age (Teller Acuity Card Test)
Number of subjects: 109
Study 26576709 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT plus brachytherapy (40 to 50.4 Gy)
Number of subjects: 20279
Study 26576709 — intervention group
Group type: COMPARATOR
Intervention: EBRT alone (75.6 to 81 Gy)
Number of subjects: 20279
Study 26576709 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT plus brachytherapy
Number of subjects: 20279
Study 24705337 — intervention group
Group type: EXPERIMENTAL
Intervention: MEmory Specificity Training (MEST)
Number of subjects: 24
Study 24705337 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional contact)
Number of subjects: 24
Study 22647290 — intervention group
Group type: EXPERIMENTAL
Intervention: Set of eight revised Forever Free booklets
Number of subjects: 1400
Study 22647290 — intervention group
Group type: COMPARATOR
Intervention: Leaflet that has no evidence to suggest it is effective
Number of subjects: 1400
Study 2826100 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Qigong (MQ)
Number of subjects: 162
Study 2826100 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 162
Study 17717604 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled NO (iNO; 80 ppm)
Number of subjects: 20
Study 17717604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15479686 — intervention group
Group type: EXPERIMENTAL
Intervention: Alicaforsen enema (4 mg/ml)
Number of subjects: 40
Study 15479686 — intervention group
Group type: EXPERIMENTAL
Intervention: Alicaforsen enema (2 mg/ml)
Number of subjects: 40
Study 15479686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11476359 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 1184
Study 11476359 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 1184
Study 9311956 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturally occurring beta-carotene (BC) derived from Dunaliella bardawil (64 mg tBC, 69 mg 9cBC)
Number of subjects: 12
Study 9311956 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 12
Study 7932066 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 129
Study 7932066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 3246465 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced training frequency from 3 days/week to 2 days/week (n = 9), 1 day/week (n = 7), or 0 days/week (n = 2).
Number of subjects: 50
Study 3246465 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced training frequency from 2 days/week to 1 day/week (n = 12) or 0 days/week (n = 11).
Number of subjects: 50
Study 3246465 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 9) who did not train.
Number of subjects: 50
Study 30509224 — intervention group
Group type: EXPERIMENTAL
Intervention: FFIT for Women
Number of subjects: 123
Study 27684632 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water intake (200 ml at 98.6°F/37°C in the fourth postoperative hour)
Number of subjects: 60
Study 27684632 — intervention group
Group type: COMPARATOR
Intervention: Control group (no warm water intake)
Number of subjects: 60
Study 27684632 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water intake
Number of subjects: 60
Study 23999999 — intervention group
Group type: EXPERIMENTAL
Intervention: Four serum miRNAs (miR‐22, miR‐572, miR‐638, and miR‐1234) used to construct a miRNA signature.
Number of subjects: 512
Study 23999999 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of the miRNA signature and TNM stage.
Number of subjects: 512
Study 22624833 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose clopidogrel
Number of subjects: 1028
Study 22624833 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose clopidogrel
Number of subjects: 1028
Study 20592293 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 209
Study 20592293 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 209
Study 18246361 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid fitting based on the NAL-RP formula (prescriptive procedure)
Number of subjects: 0
Study 18246361 — intervention group
Group type: COMPARATOR
Intervention: Comparative fitting procedure (optimizing speech intelligibility scores)
Number of subjects: 0
Study 17206944 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 600 IU/day plus ascorbic acid 500 mg/day (group B)
Number of subjects: 90
Study 17206944 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced calorie diet and physical exercise (group A)
Number of subjects: 90
Study 17206944 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 90
Study 17206944 — intervention group
Group type: COMPARATOR
Intervention: Alpha-tocopherol and ascorbic acid (group B)
Number of subjects: 90
Study 12833187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure threshold inspiratory muscle training
Number of subjects: 42
Study 12833187 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted resistive inspiratory muscle training
Number of subjects: 42
Study 12833187 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 10370197 — intervention group
Group type: EXPERIMENTAL
Intervention: DLPC liposomes
Number of subjects: 11
Study 10370197 — intervention group
Group type: EXPERIMENTAL
Intervention: DPPC liposomes
Number of subjects: 11
Study 8909662 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. prochlorperazine 0.1 mg.kg‐1
Number of subjects: 0
Study 8909662 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. prochlorperazine 0.2 mg.kg‐1
Number of subjects: 0
Study 8909662 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ondansetron 0.06 mg.kg‐1
Number of subjects: 0
Study 8909662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1875403 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 40
Study 1875403 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus goal setting
Number of subjects: 40
Study 1875403 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 40
Study 6362091 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate heparinization
Number of subjects: 45
Study 6362091 — intervention group
Group type: COMPARATOR
Intervention: No immediate anticoagulation
Number of subjects: 45
Study 31434094 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional AVM treatment (surgical resection, endovascular therapy, stereotactic radiosurgery)
Number of subjects: 0
Study 31434094 — intervention group
Group type: COMPARATOR
Intervention: Medical management (implied control)
Number of subjects: 0
Study 29574974 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 2.25-3 mg BID in transplant patients
Number of subjects: 0
Study 29574974 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 3.75 mg BID for oncological indications
Number of subjects: 0
Study 27187464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra Rice(®) (UR(®)) fortified with iron, zinc, thiamin and folic acid
Number of subjects: 99
Study 27187464 — intervention group
Group type: COMPARATOR
Intervention: Polished rice
Number of subjects: 99
Study 24478323 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (sensorimotor, endurance, and strength training twice a week for 36 weeks)
Number of subjects: 61
Study 24478323 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 61
Study 24478323 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 61
Study 22583635 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence cystoscopy
Number of subjects: 551
Study 22583635 — intervention group
Group type: COMPARATOR
Intervention: White light cystoscopy
Number of subjects: 551
Study 19171009 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more doses of sulfadoxine-pyrimethamine (SP)
Number of subjects: 1441
Study 19171009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp)
Number of subjects: 1441
Study 19171009 — intervention group
Group type: EXPERIMENTAL
Intervention: Each increment in number of SP doses
Number of subjects: 1441
Study 17573796 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 tablets (48 g) of sodium phosphate (NaP)
Number of subjects: 481
Study 17573796 — intervention group
Group type: COMPARATOR
Intervention: 2L polyethylene glycol (PEG) solution plus 4 (20 mg) bisacodyl tablets
Number of subjects: 481
Study 15833091 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg per day
Number of subjects: 0
Study 15833091 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg per day
Number of subjects: 0
Study 15833091 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg per day)
Number of subjects: 0
Study 15833091 — intervention group
Group type: COMPARATOR
Intervention: Topiramate (100 or 200 mg per day)
Number of subjects: 0
Study 11812917 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa, 150-300 IU/kg or 10,000-20,000 IU, three times weekly
Number of subjects: 7000
Study 11812917 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa, once-weekly dosing
Number of subjects: 7000
Study 11812917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7000
Study 9830579 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cholelithiasis
Number of subjects: 500
Study 9830579 — intervention group
Group type: COMPARATOR
Intervention: Patients without cholelithiasis
Number of subjects: 500
Study 7662078 — intervention group
Group type: EXPERIMENTAL
Intervention: Otovent-supported middle ear aeration before and after adenoidectomy
Number of subjects: 146
Study 7662078 — intervention group
Group type: COMPARATOR
Intervention: Adenoidectomy followed by paracentesis (Control)
Number of subjects: 146
Study 2520419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed infrared laser treatment, 12 sessions on alternate days, total energy dose of 5 J each, targeting four painful muscular trigger points and five acupuncture points.
Number of subjects: 0
Study 2520419 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment, 12 sessions on alternate days, identical procedure to the intervention group but with nonoperational laser apparatus.
Number of subjects: 0
Study 1036663 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets containing proteins (3.0 g of N from rice plus 3.0 g of N from milk)
Number of subjects: 0
Study 1036663 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets containing proteins (3.0 g of N from rice plus 3.0 g of N from wheat flour)
Number of subjects: 0
Study 1036663 — intervention group
Group type: COMPARATOR
Intervention: Crystalline amino acids
Number of subjects: 0
Study 1036663 — intervention group
Group type: COMPARATOR
Intervention: Diets containing amino acids instead of rice plus wheat
Number of subjects: 0
Study 31851290 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital transfusion of 2 U of plasma
Number of subjects: 626
Study 31851290 — intervention group
Group type: COMPARATOR
Intervention: Standard care (crystalloid-based resuscitation)
Number of subjects: 626
Study 30510604 — intervention group
Group type: EXPERIMENTAL
Intervention: P/F ratio ≤ 200 in the respiratory insufficiency group
Number of subjects: 262
Study 30510604 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation duration in the nonrespiratory insufficiency group
Number of subjects: 262
Study 30510604 — intervention group
Group type: EXPERIMENTAL
Intervention: P/F ratio in the respiratory insufficiency group
Number of subjects: 262
Study 27506222 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 1398
Study 27506222 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 1398
Study 27506222 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Number of subjects: 1398
Study 27506222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1398
Study 24479254 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculovestibular recoupling
Number of subjects: 29
Study 24479254 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study 24261110 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic intra-operative phone calls every two hours
Number of subjects: 117
Study 24261110 — intervention group
Group type: COMPARATOR
Intervention: No periodic phone calls
Number of subjects: 117
Study 20804444 — intervention group
Group type: EXPERIMENTAL
Intervention: DPSGC 25 mg
Number of subjects: 100
Study 20804444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19128713 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 10 mg/mL ropivacaine hydrochloride with epinephrine (n=19)
Number of subjects: 58
Study 19128713 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 2.5 mg/mL bupivacaine with epinephrine (n=20)
Number of subjects: 58
Study 19128713 — intervention group
Group type: COMPARATOR
Intervention: Saline with epinephrine (n=19)
Number of subjects: 58
Study 19128713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine group
Number of subjects: 58
Study 19128713 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine group
Number of subjects: 58
Study 16501426 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (80 mg/day)
Number of subjects: 550
Study 16501426 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus heparin (80 mg/day + 5000 IU unfractionated heparin subcutaneously 12 hourly)
Number of subjects: 550
Study 16501426 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus heparin
Number of subjects: 550
Study 16501426 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 550
Study 16501426 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 550
Study 12871893 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-menopausal hormone therapy (pHT) regimens including any estrogen, any estrogen plus any progestin, or tibolone
Number of subjects: 39
Study 12871893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (synthetic progestin)
Number of subjects: 39
Study 12871893 — intervention group
Group type: EXPERIMENTAL
Intervention: Any estrogen compound
Number of subjects: 39
Study 10952827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Doppler measurements of mitral inflow velocities and early inflow deceleration time
Number of subjects: 3022
Study 8793701 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological management (dietary therapy, restriction of alcohol consumption, exercise)
Number of subjects: 100
Study 8793701 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological management (restriction of sodium intake, behavioral therapy)
Number of subjects: 100
Study 8793701 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological management
Number of subjects: 100
Study 1499708 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid (90-100%)
Number of subjects: 33
Study 1499708 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled water (74-84%)
Number of subjects: 33
Study 1499708 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (37-49%, at 2 microM)
Number of subjects: 33
Study 1499708 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid (100 mM)
Number of subjects: 33
Study 1499708 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid (300 mM)
Number of subjects: 33
Study 1499708 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid (1 M)
Number of subjects: 33
Study 1499708 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (3 microM)
Number of subjects: 33
Study 1499708 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (10, 30, 100 microM)
Number of subjects: 33
Study 1499708 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (100 microM)
Number of subjects: 33
Study 6500764 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone 300 mg per day
Number of subjects: 0
Study 6500764 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 1200 mg per day
Number of subjects: 0